Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Shinichi Tamura | Founder & Chairman of the Board | 233M | -- | 1949 |
| Mr. Christopher Cargill | Representative Executive Officer, President, CEO & Director | 200M | -- | 1984 |
| Mr. Hironoshin Nomura | Executive Officer, Executive VP & CFO | -- | -- | 1983 |
| Mr. Toshihiro Maeda | Executive VP & COO | -- | -- | 1979 |
| Mr. Kieran Johnson F.C.A. | Executive Officer, Executive VP & Chief Accounting Officer | -- | -- | 1969 |
| Mr. Kazuhiko Yoshizumi | Executive Officer, Executive VP & Chief Compliance Officer | -- | -- | 1954 |
| Mr. Shinichiro Nishishita | VP of Investor Relations & Head of Regulatory Disclosures | -- | -- | -- |
| Stacey Southall | Associate Director & Head of Biophysics | -- | -- | -- |
| Ms. Candelle Chong | Executive Officer, Executive VP, CEO Office & Chief of Staff | -- | -- | 1989 |
| Mr. Patrick Branch | Head of Business Development for Japan and the APAC region | -- | -- | -- |
Nxera Pharma Co., Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 374
Description
Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist in phase 2 trial for narcolepsy and preclinical trial for EDS in neurology. Its products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; PF-06954522, a GLP-1 agonist for metabolic diseases; and NBI-1117570, a dual muscarinic M1/M4 agonist, NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; NXE0048149, a GPR52 agonist for schizophrenia; and NXE0039732, an EP4 antagonist for immuno-oncology. The company's products in preclinical trial comprise NBI-1117567, a muscarinic M1-preferring agonist for neurology; KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. It also develops other discovery-stage drugs. The company has strategic collaborations with Verily, PeptiDream, Tempero Bio, Pharmenable Therapeutics, Kallyope, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Boehringer Ingelheim, Lilly, AbbVie, Biohaven pharmaceuticals, Takeda, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and PrecisionLife. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato-ku, Japan.
Corporate Governance
Upcoming Events
May 7, 2025 at 6:30 AM UTC - May 12, 2025 at 6:30 AM UTC
Nxera Pharma Co., Ltd. Earnings Date
Recent Events
March 27, 2015 at 12:00 AM UTC
Ex-Dividend Date